Major Study on Chelation Therapy for Heart Disease

Oct. 31, 2012 - PRLog -- Chelation therapy for heart and vascular disease is a controversial alternative therapy that might become proven effective by TACT (the Trial to Assess Chelation Therapy).

TACT is a 7-year study funded by the NIH and carried out by university cardiologists and experienced chelation physicians from around the United States.  This randomized, double-blind study compared patients who had previous heart attacks who were treated with medications with or without intravenous chelation therapy.  The results of TACT will be presented at the American Heart Association meeting November 4, 2012 in Los Angeles.

Chelation, from the Greek word “chele” meaning claw, implies that an organic molecule binds a cation (charged mineral) in a pincer-like fashion, forming a heterocyclic ring structure.The most widely accepted use of chelation therapy is for the removal of toxic minerals such as lead from the body. A more controversial indication, discovered serendipitously during treatment of patients suffering with lead toxicity involving the use of the chelating agent disodium ethylene diaminetetraacetic acid (EDTA), is in the treatment of all forms of atherosclerotic cardiovascular disease.

For more information on the development of EDTA Chelation Therapy go to www.chelation.me.